{
    "hands_on_practices": [
        {
            "introduction": "Maintaining the chemical stability of a drug is a cornerstone of formulation development, especially for sensitive molecules in aqueous solutions like parenteral products. The $\\mathrm{pH}$ of the formulation is a master variable controlling degradation rates, and buffers are employed to resist $\\mathrm{pH}$ shifts. This exercise challenges you to derive the expression for buffer capacity, a key measure of a buffer's effectiveness, directly from fundamental laws of mass action and conservation, and then apply it to a practical scenario involving a phosphate-buffered formulation. Mastering this principle allows you to quantitatively assess and optimize the robustness of a formulation's $\\mathrm{pH}$ control system .",
            "id": "5015833",
            "problem": "A parenteral formulation intended for intravenous administration uses a sodium phosphate buffer to maintain chemical stability of a labile small-molecule drug during storage and infusion. At temperature $25\\,^{\\circ}\\mathrm{C}$, the formulation contains a total analytical phosphate concentration $C_{\\mathrm{P}} = 0.020~\\mathrm{mol}\\,\\mathrm{L}^{-1}$ and is adjusted to a $\\mathrm{pH}$ (potential of hydrogen) of $7.40$. Near neutral $\\mathrm{pH}$, the relevant phosphate acid-base pair is $\\mathrm{H_{2}PO_{4}^{-}}/\\mathrm{HPO_{4}^{2-}}$, governed by the second dissociation of phosphoric acid with acid dissociation constant $K_{a,2}$. Assume ideal solution behavior (activity coefficients equal to $1$), negligible volume change upon titration, and that, at this $\\mathrm{pH}$, contributions from $\\mathrm{H_{3}PO_{4}}$ and $\\mathrm{PO_{4}^{3-}}$ can be neglected. The ionic product of water at $25\\,^{\\circ}\\mathrm{C}$ is $K_{w}$.\n\nStarting strictly from the law of mass action, conservation of mass for total phosphate, and conservation of protons under addition of a strong acid, derive the expression for the buffer capacity $\\beta$ defined as the positive quantity equal to the absolute value of the slope of the number of moles of added strong acid per liter with respect to $\\mathrm{pH}$ at constant temperature and volume. Then compute $\\beta$ at $\\mathrm{pH}=7.40$ using $K_{a,2} = 6.31 \\times 10^{-8}$ and $K_{w} = 1.00 \\times 10^{-14}$. \n\nExpress your final answer in $\\mathrm{mol}\\,\\mathrm{L}^{-1}$ per unit $\\mathrm{pH}$ and round your answer to four significant figures.",
            "solution": "The problem requires the derivation of the buffer capacity, $\\beta$, for a sodium phosphate buffer system, followed by its calculation at a specific $\\mathrm{pH}$. The derivation must start from fundamental principles.\n\n### Step 1: Derivation of the Buffer Capacity Expression\n\nThe buffer capacity $\\beta$ is defined as the positive quantity equal to the absolute value of the slope of the number of moles of added strong acid per liter, $C_A$, with respect to $\\mathrm{pH}$. Mathematically, this is $\\beta = |\\frac{dC_A}{d(\\mathrm{pH})}|$. Since adding a strong acid decreases the $\\mathrm{pH}$, the derivative $\\frac{dC_A}{d(\\mathrm{pH})}$ is negative. Therefore, the definition is equivalent to the standard definition of buffer index, $\\beta = -\\frac{dC_A}{d(\\mathrm{pH})}$.\n\nWe begin by establishing the governing equations for the system at equilibrium.\n1.  **Law of Mass Action for Water:** The autoionization of water is described by the ionic product of water, $K_w$.\n    $$K_w = [\\mathrm{H}^{+}] [\\mathrm{OH}^{-}]$$\n\n2.  **Law of Mass Action for Phosphate Buffer:** Near neutral $\\mathrm{pH}$, the relevant equilibrium is the second dissociation of phosphoric acid ($\\mathrm{H_3PO_4}$), involving the conjugate acid-base pair $\\mathrm{H_2PO_4^{-}}/\\mathrm{HPO_4^{2-}}$.\n    $$\\mathrm{H_2PO_4^{-}} \\rightleftharpoons \\mathrm{H}^{+} + \\mathrm{HPO_4^{2-}}$$\n    The corresponding acid dissociation constant is $K_{a,2}$.\n    $$K_{a,2} = \\frac{[\\mathrm{H}^{+}] [\\mathrm{HPO_4^{2-}}]}{[\\mathrm{H_2PO_4^{-}}]}$$\n\n3.  **Conservation of Mass for Phosphate:** The total analytical concentration of phosphate, $C_P$, is the sum of the concentrations of the species $\\mathrm{H_2PO_4^{-}}$ and $\\mathrm{HPO_4^{2-}}$, as the contributions from $\\mathrm{H_3PO_4}$ and $\\mathrm{PO_4^{3-}}$ are assumed negligible.\n    $$C_P = [\\mathrm{H_2PO_4^{-}}] + [\\mathrm{HPO_4^{2-}}]$$\n\n4.  **Conservation of Protons (Charge Balance):** To derive an expression for $C_A$, we formulate the charge balance equation. Let us model the system as being prepared by adding a concentration $C_A$ of a strong monoprotic acid (e.g., HCl) to a solution containing a total phosphate concentration $C_P$ prepared from its conjugate base form, $\\mathrm{Na_2HPO_4}$. The species in solution are $\\mathrm{Na}^{+}$, $\\mathrm{H}^{+}$, $\\mathrm{OH}^{-}$, $\\mathrm{H_2PO_4^{-}}$, $\\mathrm{HPO_4^{2-}}$, and the anion from the strong acid, $\\mathrm{Cl}^{-}$.\n    The charge balance equation is:\n    $$[\\mathrm{Na}^{+}] + [\\mathrm{H}^{+}] = [\\mathrm{OH}^{-}] + [\\mathrm{H_2PO_4^{-}}] + 2[\\mathrm{HPO_4^{2-}}] + [\\mathrm{Cl}^{-}]$$\n    From our preparation model, the sodium ion concentration is twice the total phosphate concentration, $[\\mathrm{Na}^{+}] = 2C_P$, and the chloride ion concentration equals the concentration of added strong acid, $[\\mathrm{Cl}^{-}] = C_A$. Substituting these into the charge balance equation gives:\n    $$2C_P + [\\mathrm{H}^{+}] = [\\mathrm{OH}^{-}] + [\\mathrm{H_2PO_4^{-}}] + 2[\\mathrm{HPO_4^{2-}}] + C_A$$\n    We substitute the mass balance equation, $C_P = [\\mathrm{H_2PO_4^{-}}] + [\\mathrm{HPO_4^{2-}}]$, into this expression:\n    $$2([\\mathrm{H_2PO_4^{-}}] + [\\mathrm{HPO_4^{2-}}]) + [\\mathrm{H}^{+}] = [\\mathrm{OH}^{-}] + [\\mathrm{H_2PO_4^{-}}] + 2[\\mathrm{HPO_4^{2-}}] + C_A$$\n    Simplifying the equation by canceling terms:\n    $$[\\mathrm{H_2PO_4^{-}}] + [\\mathrm{H}^{+}] = [\\mathrm{OH}^{-}] + C_A$$\n    Rearranging to solve for $C_A$:\n    $$C_A = [\\mathrm{H_2PO_4^{-}}] + [\\mathrm{H}^{+}] - [\\mathrm{OH}^{-}]$$\n\nNow, we differentiate $C_A$ with respect to $\\mathrm{pH}$ to find $\\beta$. To do this, we must first express all terms on the right-hand side as functions of $[\\mathrm{H}^{+}]$.\nFrom the mass balance and $K_{a,2}$ expressions:\n$[\\mathrm{H_2PO_4^{-}}] = C_P - [\\mathrm{HPO_4^{2-}}]$ and $[\\mathrm{HPO_4^{2-}}] = K_{a,2} \\frac{[\\mathrm{H_2PO_4^{-}}]}{[\\mathrm{H}^{+}]}$.\n$C_P = [\\mathrm{H_2PO_4^{-}}] + K_{a,2} \\frac{[\\mathrm{H_2PO_4^{-}}]}{[\\mathrm{H}^{+}]} = [\\mathrm{H_2PO_4^{-}}] \\left(1 + \\frac{K_{a,2}}{[\\mathrm{H}^{+}]}\\right) = [\\mathrm{H_2PO_4^{-}}] \\frac{[\\mathrm{H}^{+}] + K_{a,2}}{[\\mathrm{H}^{+}]}$.\nThus, $[\\mathrm{H_2PO_4^{-}}] = C_P \\frac{[\\mathrm{H}^{+}]}{[\\mathrm{H}^{+}] + K_{a,2}}$.\nAlso, $[\\mathrm{OH}^{-}] = \\frac{K_w}{[\\mathrm{H}^{+}]}$.\nSubstituting these into the expression for $C_A$:\n$$C_A = C_P \\frac{[\\mathrm{H}^{+}]}{[\\mathrm{H}^{+}] + K_{a,2}} + [\\mathrm{H}^{+}] - \\frac{K_w}{[\\mathrm{H}^{+}]}$$\nWe now differentiate $C_A$ with respect to $\\mathrm{pH}$. We use the chain rule, noting that $\\frac{d}{d(\\mathrm{pH})} = \\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})} \\frac{d}{d[\\mathrm{H}^{+}]}$ and that $\\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})} = \\frac{d}{d(\\mathrm{pH})}(10^{-\\mathrm{pH}}) = -(\\ln 10) \\times 10^{-\\mathrm{pH}} = -(\\ln 10)[\\mathrm{H}^{+}]$.\n\nLet's find the derivatives of each term in the $C_A$ expression with respect to $\\mathrm{pH}$:\n- Term 1: $\\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})} = -(\\ln 10)[\\mathrm{H}^{+}]$.\n- Term 2: $\\frac{d[\\mathrm{OH}^{-}]}{d(\\mathrm{pH})} = \\frac{d}{d(\\mathrm{pH})} \\left( \\frac{K_w}{[\\mathrm{H}^{+}]} \\right) = -\\frac{K_w}{[\\mathrm{H}^{+}]^2} \\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})} = -\\frac{K_w}{[\\mathrm{H}^{+}]^2} (-(\\ln 10)[\\mathrm{H}^{+}]) = (\\ln 10)\\frac{K_w}{[\\mathrm{H}^{+}]} = (\\ln 10)[\\mathrm{OH}^{-}]$.\n- Term 3: $\\frac{d[\\mathrm{H_2PO_4^{-}}]}{d(\\mathrm{pH})} = \\frac{d[\\mathrm{H_2PO_4^{-}}]}{d[\\mathrm{H}^{+}]} \\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})}$.\nFirst, derivative with respect to $[\\mathrm{H}^{+}]$ using the quotient rule:\n$\\frac{d}{d[\\mathrm{H}^{+}]} \\left( C_P \\frac{[\\mathrm{H}^{+}]}{[\\mathrm{H}^{+}] + K_{a,2}} \\right) = C_P \\frac{([\\mathrm{H}^{+}] + K_{a,2})(1) - [\\mathrm{H}^{+}](1)}{([\\mathrm{H}^{+}] + K_{a,2})^2} = C_P \\frac{K_{a,2}}{([\\mathrm{H}^{+}] + K_{a,2})^2}$.\nNow multiply by $\\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})}$:\n$\\frac{d[\\mathrm{H_2PO_4^{-}}]}{d(\\mathrm{pH})} = \\left( C_P \\frac{K_{a,2}}{([\\mathrm{H}^{+}] + K_{a,2})^2} \\right) \\times (-(\\ln 10)[\\mathrm{H}^{+}]) = -(\\ln 10) C_P \\frac{K_{a,2}[\\mathrm{H}^{+}]}{([\\mathrm{H}^{+}] + K_{a,2})^2}$.\n\nNow we assemble the derivative $\\frac{dC_A}{d(\\mathrm{pH})}$:\n$$\\frac{dC_A}{d(\\mathrm{pH})} = \\frac{d[\\mathrm{H_2PO_4^{-}}]}{d(\\mathrm{pH})} + \\frac{d[\\mathrm{H}^{+}]}{d(\\mathrm{pH})} - \\frac{d[\\mathrm{OH}^{-}]}{d(\\mathrm{pH})}$$\n$$\\frac{dC_A}{d(\\mathrm{pH})} = \\left(-(\\ln 10) C_P \\frac{K_{a,2}[\\mathrm{H}^{+}]}{([\\mathrm{H}^{+}] + K_{a,2})^2}\\right) + \\left(-(\\ln 10)[\\mathrm{H}^{+}]\\right) - \\left((\\ln 10)[\\mathrm{OH}^{-}]\\right)$$\n$$\\frac{dC_A}{d(\\mathrm{pH})} = -(\\ln 10) \\left([\\mathrm{H}^{+}] + [\\mathrm{OH}^{-}] + C_P \\frac{K_{a,2}[\\mathrm{H}^{+}]}{([\\mathrm{H}^{+}] + K_{a,2})^2}\\right)$$\nFinally, we apply the definition $\\beta = -\\frac{dC_A}{d(\\mathrm{pH})}$:\n$$\\beta = (\\ln 10) \\left([\\mathrm{H}^{+}] + [\\mathrm{OH}^{-}] + C_P \\frac{K_{a,2}[\\mathrm{H}^{+}]}{([\\mathrm{H}^{+}] + K_{a,2})^2}\\right)$$\nThis is the derived expression for the buffer capacity.\n\n### Step 2: Calculation of Buffer Capacity $\\beta$\n\nWe are given the following values:\n- Total phosphate concentration, $C_P = 0.020~\\mathrm{mol}\\,\\mathrm{L}^{-1}$\n- $\\mathrm{pH} = 7.40$\n- Acid dissociation constant, $K_{a,2} = 6.31 \\times 10^{-8}$\n- Ionic product of water, $K_w = 1.00 \\times 10^{-14}$\n\nFirst, we calculate the concentrations of $\\mathrm{H}^{+}$ and $\\mathrm{OH}^{-}$ at $\\mathrm{pH} = 7.40$:\n$$[\\mathrm{H}^{+}] = 10^{-\\mathrm{pH}} = 10^{-7.40}~\\mathrm{mol}\\,\\mathrm{L}^{-1} \\approx 3.98107 \\times 10^{-8}~\\mathrm{mol}\\,\\mathrm{L}^{-1}$$\n$$[\\mathrm{OH}^{-}] = \\frac{K_w}{[\\mathrm{H}^{+}]} = \\frac{1.00 \\times 10^{-14}}{10^{-7.40}} = 10^{-6.60}~\\mathrm{mol}\\,\\mathrm{L}^{-1} \\approx 2.51189 \\times 10^{-7}~\\mathrm{mol}\\,\\mathrm{L}^{-1}$$\n\nNow, we substitute these values into the derived expression for $\\beta$. The factor $\\ln(10) \\approx 2.302585$.\nThe buffer capacity is composed of two parts: the contribution from water, $\\beta_w$, and the contribution from the phosphate buffer, $\\beta_P$.\n$$\\beta_w = (\\ln 10) ([\\mathrm{H}^{+}] + [\\mathrm{OH}^{-}]) = 2.302585 \\times (3.98107 \\times 10^{-8} + 2.51189 \\times 10^{-7}) = 2.302585 \\times (2.9100 \\times 10^{-7}) \\approx 6.7005 \\times 10^{-7}~\\mathrm{mol}\\,\\mathrm{L}^{-1}$$\n$$\\beta_P = (\\ln 10) \\left(C_P \\frac{K_{a,2}[\\mathrm{H}^{+}]}{([\\mathrm{H}^{+}] + K_{a,2})^2}\\right)$$\nWe compute the fraction first:\n$$[\\mathrm{H}^{+}] + K_{a,2} = 3.98107 \\times 10^{-8} + 6.31 \\times 10^{-8} = 1.029107 \\times 10^{-7}$$\n$$K_{a,2}[\\mathrm{H}^{+}] = (6.31 \\times 10^{-8}) \\times (3.98107 \\times 10^{-8}) = 2.51206 \\times 10^{-15}$$\n$$\\frac{K_{a,2}[\\mathrm{H}^{+}]}{([\\mathrm{H}^{+}] + K_{a,2})^2} = \\frac{2.51206 \\times 10^{-15}}{(1.029107 \\times 10^{-7})^2} = \\frac{2.51206 \\times 10^{-15}}{1.05906 \\times 10^{-14}} \\approx 0.237199$$\nNow, we calculate $\\beta_P$:\n$$\\beta_P = 2.302585 \\times (0.020~\\mathrm{mol}\\,\\mathrm{L}^{-1}) \\times 0.237199 \\approx 0.0109158~\\mathrm{mol}\\,\\mathrm{L}^{-1}$$\nThe total buffer capacity is the sum of the two contributions:\n$$\\beta = \\beta_w + \\beta_P = 6.7005 \\times 10^{-7}~\\mathrm{mol}\\,\\mathrm{L}^{-1} + 0.0109158~\\mathrm{mol}\\,\\mathrm{L}^{-1} = 0.01091647~\\mathrm{mol}\\,\\mathrm{L}^{-1}$$\nRounding the result to four significant figures as requested gives $0.01092$.",
            "answer": "$$\\boxed{0.01092}$$"
        },
        {
            "introduction": "Nanoparticle-based drug delivery systems offer tremendous potential for targeting therapies and improving the solubility of hydrophobic drugs, but their success hinges on efficiently loading the drug into the carrier. This practice explores the fundamental principle of equilibrium partitioning, which governs how a drug distributes between the nanoparticle matrix and the surrounding aqueous medium at equilibrium. By deriving and applying the relationship between total drug, phase volumes, and the partition coefficient, you will learn to predict two critical quality attributes: the amount of encapsulated drug and the final drug loading of the nanoparticles .",
            "id": "5015812",
            "problem": "A hydrophobic small-molecule drug is formulated into spherical polymeric nanoparticles by nanoprecipitation. After solvent removal, the dispersion consists of a continuous aqueous phase and a dispersed phase of solid polymer particles. At equilibrium, the drug partitions between the polymer matrix and the aqueous phase, and its equilibrium distribution is governed by a constant partition coefficient defined as $K = C_{\\mathrm{p}}/C_{\\mathrm{w}}$, where $C_{\\mathrm{p}}$ is the drug concentration in the polymer matrix and $C_{\\mathrm{w}}$ is the drug concentration in the aqueous phase. Assume ideal mixing with no specific binding sites and no chemical reactions or degradation, and that both phases are below their respective drug solubility limits.\n\nYou are provided with the following experimentally determined and formulation design parameters:\n- Total drug initially introduced: $m_{\\mathrm{tot}} = 50~\\mathrm{mg}$.\n- Total polymer mass in particles: $m_{\\mathrm{p}} = 250~\\mathrm{mg}$.\n- Polymer density: $\\rho_{\\mathrm{p}} = 1.25~\\mathrm{g}\\,\\mathrm{mL}^{-1}$.\n- Aqueous phase volume: $V_{\\mathrm{w}} = 100~\\mathrm{mL}$.\n- Drug partition coefficient between the polymer matrix and water: $K = 150$ (dimensionless), defined as above.\n- Drug solubility limits: $S_{\\mathrm{w}} = 1.0~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$ in water and $S_{\\mathrm{p}} = 100~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$ in the polymer matrix.\n\nStarting from the definitions of the partition coefficient and conservation of mass, derive the equilibrium mass of drug encapsulated in the polymer particles, $m_{\\mathrm{enc}}$, and use it to compute the drug loading $L$ defined as $L = m_{\\mathrm{enc}}/m_{\\mathrm{p}}$. Assume all polymer resides in the particles and contributes to the matrix volume, which you should obtain from $\\rho_{\\mathrm{p}}$. Verify that the computed equilibrium concentrations do not exceed $S_{\\mathrm{w}}$ and $S_{\\mathrm{p}}$. Express the final loading $L$ in $\\mathrm{mg}\\,\\mathrm{g}^{-1}$ and round your answer to four significant figures.",
            "solution": "The problem statement is first subjected to validation.\n\n**Step 1: Extract Givens**\n-   Total drug mass: $m_{\\mathrm{tot}} = 50~\\mathrm{mg}$\n-   Total polymer mass: $m_{\\mathrm{p}} = 250~\\mathrm{mg}$\n-   Polymer density: $\\rho_{\\mathrm{p}} = 1.25~\\mathrm{g}\\,\\mathrm{mL}^{-1}$\n-   Aqueous phase volume: $V_{\\mathrm{w}} = 100~\\mathrm{mL}$\n-   Drug partition coefficient: $K = 150$ (dimensionless)\n-   Definition of partition coefficient: $K = C_{\\mathrm{p}}/C_{\\mathrm{w}}$\n-   Drug concentration in polymer: $C_{\\mathrm{p}}$\n-   Drug concentration in water: $C_{\\mathrm{w}}$\n-   Drug solubility in water: $S_{\\mathrm{w}} = 1.0~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$\n-   Drug solubility in polymer: $S_{\\mathrm{p}} = 100~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$\n-   Target variable: Drug loading $L = m_{\\mathrm{enc}}/m_{\\mathrm{p}}$, where $m_{\\mathrm{enc}}$ is the encapsulated mass of the drug.\n-   Assumptions: Equilibrium partitioning, ideal mixing, no reactions, concentrations below solubility limits.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, describing a standard equilibrium partitioning phenomenon common in pharmaceutical sciences. It is well-posed, providing all necessary parameters and two fundamental principles (mass conservation and partition equilibrium) to solve for the two primary unknowns (drug mass in each phase). The problem is objective and uses precise terminology. There are no contradictions; the given parameters are physically plausible. The verification step to check concentrations against solubilities is an internal consistency check, which reinforces the validity of the problem setup.\n\n**Step 3: Verdict and Action**\nThe problem is **valid**. A solution will be derived.\n\nThe solution is based on two fundamental principles: conservation of mass and the definition of equilibrium partitioning.\n\nLet $m_{\\mathrm{enc}}$ be the mass of the drug encapsulated in the polymer particles and $m_{\\mathrm{w}}$ be the mass of the drug dissolved in the aqueous phase. The total mass of the drug, $m_{\\mathrm{tot}}$, is conserved.\n$$m_{\\mathrm{tot}} = m_{\\mathrm{enc}} + m_{\\mathrm{w}}$$\n\nLet $C_{\\mathrm{p}}$ be the concentration of the drug in the polymer phase and $C_{\\mathrm{w}}$ be the concentration of the drug in the aqueous phase. These are defined as mass per unit volume.\n$$C_{\\mathrm{p}} = \\frac{m_{\\mathrm{enc}}}{V_{\\mathrm{p}}}$$\n$$C_{\\mathrm{w}} = \\frac{m_{\\mathrm{w}}}{V_{\\mathrm{w}}}$$\nHere, $V_{\\mathrm{w}}$ is the volume of the aqueous phase, given as $100~\\mathrm{mL}$. The volume of the polymer phase, $V_{\\mathrm{p}}$, is not given directly but can be calculated from the polymer mass, $m_{\\mathrm{p}}$, and its density, $\\rho_{\\mathrm{p}}$.\nFirst, we convert the polymer mass to grams to be consistent with the density units:\n$m_{\\mathrm{p}} = 250~\\mathrm{mg} = 0.250~\\mathrm{g}$\nNow, we calculate $V_{\\mathrm{p}}$:\n$$V_{\\mathrm{p}} = \\frac{m_{\\mathrm{p}}}{\\rho_{\\mathrm{p}}} = \\frac{0.250~\\mathrm{g}}{1.25~\\mathrm{g}\\,\\mathrm{mL}^{-1}} = 0.200~\\mathrm{mL}$$\n\nThe equilibrium partition coefficient, $K$, relates the concentrations in the two phases:\n$$K = \\frac{C_{\\mathrm{p}}}{C_{\\mathrm{w}}}$$\nSubstituting the definitions of concentration gives:\n$$K = \\frac{m_{\\mathrm{enc}}/V_{\\mathrm{p}}}{m_{\\mathrm{w}}/V_{\\mathrm{w}}} = \\frac{m_{\\mathrm{enc}}V_{\\mathrm{w}}}{m_{\\mathrm{w}}V_{\\mathrm{p}}}$$\nWe have a system of two equations with two unknowns, $m_{\\mathrm{enc}}$ and $m_{\\mathrm{w}}$. We solve for $m_{\\mathrm{enc}}$. From the mass conservation equation, we express $m_{\\mathrm{w}}$ as:\n$$m_{\\mathrm{w}} = m_{\\mathrm{tot}} - m_{\\mathrm{enc}}$$\nSubstituting this expression into the partition coefficient equation:\n$$K = \\frac{m_{\\mathrm{enc}}V_{\\mathrm{w}}}{(m_{\\mathrm{tot}} - m_{\\mathrm{enc}})V_{\\mathrm{p}}}$$\nWe now algebraically solve for $m_{\\mathrm{enc}}$:\n$$K(m_{\\mathrm{tot}} - m_{\\mathrm{enc}})V_{\\mathrm{p}} = m_{\\mathrm{enc}}V_{\\mathrm{w}}$$\n$$K m_{\\mathrm{tot}} V_{\\mathrm{p}} - K m_{\\mathrm{enc}} V_{\\mathrm{p}} = m_{\\mathrm{enc}}V_{\\mathrm{w}}$$\n$$K m_{\\mathrm{tot}} V_{\\mathrm{p}} = m_{\\mathrm{enc}}V_{\\mathrm{w}} + K m_{\\mathrm{enc}} V_{\\mathrm{p}}$$\n$$K m_{\\mathrm{tot}} V_{\\mathrm{p}} = m_{\\mathrm{enc}}(V_{\\mathrm{w}} + K V_{\\mathrm{p}})$$\n$$m_{\\mathrm{enc}} = \\frac{K V_{\\mathrm{p}} m_{\\mathrm{tot}}}{V_{\\mathrm{w}} + K V_{\\mathrm{p}}}$$\nNow we substitute the provided numerical values: $K = 150$, $V_{\\mathrm{p}} = 0.200~\\mathrm{mL}$, $m_{\\mathrm{tot}} = 50~\\mathrm{mg}$, and $V_{\\mathrm{w}} = 100~\\mathrm{mL}$.\n$$m_{\\mathrm{enc}} = \\frac{(150)(0.200~\\mathrm{mL})(50~\\mathrm{mg})}{100~\\mathrm{mL} + (150)(0.200~\\mathrm{mL})} = \\frac{1500~\\mathrm{mg}\\cdot\\mathrm{mL}}{100~\\mathrm{mL} + 30~\\mathrm{mL}} = \\frac{1500~\\mathrm{mg}\\cdot\\mathrm{mL}}{130~\\mathrm{mL}} = \\frac{150}{13}~\\mathrm{mg}$$\nNumerically, $m_{\\mathrm{enc}} \\approx 11.538~\\mathrm{mg}$.\n\nThe problem requires a verification that the equilibrium concentrations do not exceed their respective solubility limits.\nFirst, we find the drug mass in the aqueous phase, $m_{\\mathrm{w}}$:\n$$m_{\\mathrm{w}} = m_{\\mathrm{tot}} - m_{\\mathrm{enc}} = 50~\\mathrm{mg} - \\frac{150}{13}~\\mathrm{mg} = \\frac{650 - 150}{13}~\\mathrm{mg} = \\frac{500}{13}~\\mathrm{mg} \\approx 38.462~\\mathrm{mg}$$\nNow we calculate the concentrations:\n$$C_{\\mathrm{w}} = \\frac{m_{\\mathrm{w}}}{V_{\\mathrm{w}}} = \\frac{500/13~\\mathrm{mg}}{100~\\mathrm{mL}} = \\frac{5}{13}~\\mathrm{mg}\\,\\mathrm{mL}^{-1} \\approx 0.3846~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$$\n$$C_{\\mathrm{p}} = \\frac{m_{\\mathrm{enc}}}{V_{\\mathrm{p}}} = \\frac{150/13~\\mathrm{mg}}{0.200~\\mathrm{mL}} = \\frac{750}{13}~\\mathrm{mg}\\,\\mathrm{mL}^{-1} \\approx 57.692~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$$\nWe compare these to the solubility limits:\n- For the aqueous phase: $C_{\\mathrm{w}} \\approx 0.3846~\\mathrm{mg}\\,\\mathrm{mL}^{-1} < S_{\\mathrm{w}} = 1.0~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$. This condition is satisfied.\n- For the polymer phase: $C_{\\mathrm{p}} \\approx 57.692~\\mathrm{mg}\\,\\mathrm{mL}^{-1} < S_{\\mathrm{p}} = 100~\\mathrm{mg}\\,\\mathrm{mL}^{-1}$. This condition is also satisfied.\nThe calculations are consistent with the problem's constraints.\n\nFinally, we compute the drug loading, $L$, defined as $L = m_{\\mathrm{enc}}/m_{\\mathrm{p}}$. The desired units are $\\mathrm{mg}\\,\\mathrm{g}^{-1}$, so we use $m_{\\mathrm{p}}$ in grams.\n$$L = \\frac{m_{\\mathrm{enc}}}{m_{\\mathrm{p}}} = \\frac{150/13~\\mathrm{mg}}{0.250~\\mathrm{g}} = \\frac{150}{13 \\times 0.250}~\\mathrm{mg}\\,\\mathrm{g}^{-1} = \\frac{600}{13}~\\mathrm{mg}\\,\\mathrm{g}^{-1}$$\n$$L \\approx 46.153846...~\\mathrm{mg}\\,\\mathrm{g}^{-1}$$\nRounding to four significant figures, the drug loading is $46.15~\\mathrm{mg}\\,\\mathrm{g}^{-1}$.",
            "answer": "$$\\boxed{46.15}$$"
        },
        {
            "introduction": "The ultimate goal of formulation development is to achieve a desired therapeutic outcome in patients, a process that is rigorously evaluated through clinical studies and regulatory frameworks like bioequivalence testing. This advanced exercise connects the design of a modified-release (MR) formulation directly to its clinical pharmacokinetic (PK) performance and the statistical requirements of a bioequivalence trial. You will model how changing a formulation's release duration, $T$, alters the peak plasma concentration, $C_{\\max}$, and then use this model to predict the sample size needed to demonstrate bioequivalence, showcasing the power of PK modeling in guiding late-stage formulation decisions .",
            "id": "5015802",
            "problem": "A single-dose Modified-Release (MR) oral formulation is designed to deliver a constant input rate to the systemic circulation over a finite release window. Consider a reference MR product with release duration $T_{R}$ and a test MR product with release duration $T_{T}$, both administering the same dose. Assume linear one-compartment pharmacokinetics with first-order elimination, bioavailability $F$, dose $D$, clearance $\\text{CL}$, and elimination rate constant $k$ related to the half-life $t_{1/2}$ through $k = \\ln(2)/t_{1/2}$. During the release window of duration $T$, the input rate is constant and equals the total absorbed amount divided by $T$. Outside this window, input is zero. \n\nStarting from mass balance for the central compartment and the one-compartment linear pharmacokinetic model, derive the concentration-time function during the release window and show that the peak concentration occurs at the end of the release window. Then, obtain an expression for the peak concentration $C_{\\max}(T)$ as a function of $F$, $D$, $\\text{CL}$, $k$, and $T$, and use it to construct the test-to-reference geometric mean ratio for peak concentration,\n$$\n\\text{GMR}_{C_{\\max}} = \\frac{C_{\\max}(T_{T})}{C_{\\max}(T_{R})}.\n$$\n\nFor a translational medicine scenario, take realistic values: $F = 0.8$, $D = 500$ (mg), $\\text{CL} = 20$ (L/h), $t_{1/2} = 6$ (h), $T_{R} = 12$ (h), and $T_{T} = 8$ (h). Assume within-subject variability of $C_{\\max}$ is lognormal with Coefficient of Variation (CV) on the original scale equal to $0.25$. In a standard two-sequence, two-period crossover bioequivalence (BE) design evaluated by Two One-Sided Tests (TOST), the $0.90$ confidence interval for the geometric mean ratio must lie entirely within $[0.8, 1.25]$. Under the normal approximation on the log scale, the half-width of the confidence interval is given by the product of a standard normal critical value, the standard error, and appropriate model-based quantities.\n\nUsing the natural logarithm throughout, compute the smallest whole number of subjects $N$ (total across both sequences) required such that, for the model-predicted $\\text{GMR}_{C_{\\max}}$, the $0.90$ confidence interval on the log scale lies entirely within the BE limits. Report only the minimal $N$ that satisfies this criterion. Do not report any intermediate values. The final answer is unitless and must be a single number.",
            "solution": "The problem is first validated to ensure it is scientifically sound, self-contained, and well-posed.\n\n### Step 1: Extract Givens\n- **Model**: Single-dose Modified-Release (MR) oral formulation, linear one-compartment pharmacokinetics, first-order elimination, zero-order input over a finite duration $T$.\n- **Input Model**: Constant input rate $R_{in}$ for a duration $T$, where $R_{in}$ is the total absorbed amount divided by $T$. Input is zero outside this window. Total absorbed amount is $F \\cdot D$.\n- **Pharmacokinetic Parameters**:\n    - Bioavailability: $F$\n    - Dose: $D$\n    - Clearance: $\\text{CL}$\n    - Elimination rate constant: $k$\n    - Half-life: $t_{1/2}$, related by $k = \\ln(2)/t_{1/2}$\n- **Products**:\n    - Reference (R): Release duration $T_R$\n    - Test (T): Release duration $T_T$\n- **Objective 1**: Derive concentration-time function $C(t)$ during release, show $C_{\\max}$ occurs at $t=T$, and derive $C_{\\max}(T) = f(F, D, \\text{CL}, k, T)$.\n- **Objective 2**: Construct the geometric mean ratio $\\text{GMR}_{C_{\\max}} = C_{\\max}(T_T) / C_{\\max}(T_R)$.\n- **Objective 3**: Calculate the required number of subjects $N$ for a bioequivalence (BE) study.\n- **Numerical Values**:\n    - $F = 0.8$\n    - $D = 500$ mg\n    - $\\text{CL} = 20$ L/h\n    - $t_{1/2} = 6$ h\n    - $T_R = 12$ h\n    - $T_T = 8$ h\n- **Statistical Parameters**:\n    - Within-subject Coefficient of Variation (CV) for $C_{\\max}$: $0.25$\n    - BE study design: Two-sequence, two-period crossover.\n    - BE acceptance limits for $0.90$ confidence interval (CI): $[0.8, 1.25]$\n    - Statistical test: Two One-Sided Tests (TOST).\n    - Approximation: Normal approximation on the log scale.\n- **Final Result**: Smallest whole number of subjects $N$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is firmly based on standard, widely accepted principles of pharmacokinetics (one-compartment model, zero-order input for MR formulations) and biostatistics (bioequivalence testing using a crossover design and TOST procedure). The concepts are fundamental to translational medicine and clinical pharmacology.\n- **Well-Posed**: The problem is structured with sufficient information to derive unique and meaningful solutions. The objectives are clear and sequential.\n- **Objective**: All parameters and conditions are defined with precise, quantitative language. The values provided are realistic for a pharmaceutical product.\n\nThe problem does not violate any of the invalidity criteria. It is scientifically sound, formally structured, complete, realistic, and well-posed.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Derivation of Concentration Profile and Peak Concentration\n\nThe mass balance for the amount of drug, $A(t)$, in the central compartment is described by the differential equation:\n$$ \\frac{dA(t)}{dt} = \\text{Rate of input} - \\text{Rate of elimination} $$\nFor a zero-order input over a duration $T$ and first-order elimination, this becomes:\n$$ \\frac{dA(t)}{dt} = R_{in} - k A(t) \\quad \\text{for } 0 \\le t \\le T $$\nThe constant input rate, $R_{in}$, is the total absorbed dose ($F \\cdot D$) divided by the release duration $T$:\n$$ R_{in} = \\frac{F \\cdot D}{T} $$\nThe differential equation is a first-order linear non-homogeneous ordinary differential equation. We solve it with the initial condition $A(0) = 0$, as there is no drug in the body at time $t=0$. The solution is:\n$$ A(t) = \\frac{R_{in}}{k} (1 - \\exp(-kt)) $$\nThe concentration in plasma, $C(t)$, is the amount divided by the volume of distribution, $V_d$:\n$$ C(t) = \\frac{A(t)}{V_d} $$\nWe are given clearance, $\\text{CL}$, which is related to $k$ and $V_d$ by $\\text{CL} = k \\cdot V_d$. Therefore, $V_d = \\text{CL}/k$. Substituting this into the equation for $C(t)$:\n$$ C(t) = \\frac{A(t)}{\\text{CL}/k} = \\frac{k}{\\text{CL}} \\left[ \\frac{R_{in}}{k} (1 - \\exp(-kt)) \\right] = \\frac{R_{in}}{\\text{CL}} (1 - \\exp(-kt)) $$\nSubstituting the expression for $R_{in}$:\n$$ C(t) = \\frac{F \\cdot D}{T \\cdot \\text{CL}} (1 - \\exp(-kt)) \\quad \\text{for } 0 \\le t \\le T $$\nTo find the time of peak concentration, we examine the derivative of $C(t)$ with respect to time $t$:\n$$ \\frac{dC(t)}{dt} = \\frac{d}{dt} \\left[ \\frac{F \\cdot D}{T \\cdot \\text{CL}} (1 - \\exp(-kt)) \\right] = \\frac{F \\cdot D}{T \\cdot \\text{CL}} (k \\exp(-kt)) $$\nSince $F$, $D$, $T$, $\\text{CL}$, and $k$ are all positive constants, and $\\exp(-kt)$ is positive for all finite $t$, the derivative $\\frac{dC(t)}{dt}$ is strictly positive for all $t$ in the release interval $[0, T]$. This indicates that $C(t)$ is a monotonically increasing function throughout the input phase. Consequently, the peak concentration, $C_{\\max}$, occurs at the end of the release window, i.e., at $t=T$.\n\nThe expression for the peak concentration, $C_{\\max}(T)$, is thus $C(t=T)$:\n$$ C_{\\max}(T) = \\frac{F \\cdot D}{T \\cdot \\text{CL}} (1 - \\exp(-kT)) $$\nNext, we construct the test-to-reference geometric mean ratio for peak concentration, $\\text{GMR}_{C_{\\max}}$. The parameters $F$, $D$, $\\text{CL}$, and $k$ are assumed to be identical for both formulations.\n$$ \\text{GMR}_{C_{\\max}} = \\frac{C_{\\max}(T_T)}{C_{\\max}(T_R)} = \\frac{\\frac{F \\cdot D}{T_T \\cdot \\text{CL}} (1 - \\exp(-kT_T))}{\\frac{F \\cdot D}{T_R \\cdot \\text{CL}} (1 - \\exp(-kT_R))} $$\nSimplifying the expression yields:\n$$ \\text{GMR}_{C_{\\max}} = \\frac{T_R}{T_T} \\frac{1 - \\exp(-kT_T)}{1 - \\exp(-kT_R)} $$\n\n### Sample Size Calculation for Bioequivalence Study\n\nThe final task is to calculate the minimum number of subjects, $N$, required for a bioequivalence study. The analysis is performed on the natural logarithm of the data. The condition is that the $90\\%$ confidence interval for the geometric mean ratio lies entirely within the bioequivalence limits of $[0.8, 1.25]$. On the log scale, this corresponds to the interval $[\\ln(0.8), \\ln(1.25)]$.\n\nThe point estimate for the difference of means on the log scale is $\\hat{\\delta} = \\ln(\\text{GMR}_{C_{\\max}})$.\nThe within-subject variance on the log scale, $\\sigma_W^2$, is related to the given within-subject coefficient of variation (CV) on the original scale by $\\sigma_W^2 = \\ln(\\text{CV}^2 + 1)$.\nFor a $2 \\times 2$ crossover design, the $90\\%$ confidence interval for the true mean difference is estimated as:\n$$ \\hat{\\delta} \\pm z_{1-\\alpha} \\sqrt{\\frac{2 \\sigma_W^2}{N}} $$\nFor TOST, two one-sided tests are performed at level $\\alpha=0.05$. The corresponding confidence interval is a $1-2\\alpha = 1-0.10=0.90$ interval. The critical value from the standard normal distribution is $z_{1-\\alpha} = z_{0.95} \\approx 1.64485$.\n\nThe BE limits on the log scale are $\\theta_L = \\ln(0.8)$ and $\\theta_U = \\ln(1.25)$. The CI must satisfy:\n1. $\\hat{\\delta} - z_{0.95} \\sqrt{\\frac{2 \\sigma_W^2}{N}} > \\theta_L$\n2. $\\hat{\\delta} + z_{0.95} \\sqrt{\\frac{2 \\sigma_W^2}{N}} < \\theta_U$\n\nLet's first calculate the numerical values for the parameters.\n$k = \\frac{\\ln(2)}{t_{1/2}} = \\frac{\\ln(2)}{6} \\, \\text{h}^{-1}$.\n$T_T = 8$ h, $T_R = 12$ h.\n$$ \\text{GMR}_{C_{\\max}} = \\frac{12}{8} \\frac{1 - \\exp(-\\frac{\\ln(2)}{6} \\cdot 8)}{1 - \\exp(-\\frac{\\ln(2)}{6} \\cdot 12)} = 1.5 \\frac{1 - \\exp(-\\frac{4}{3}\\ln(2))}{1 - \\exp(-2\\ln(2))} = 1.5 \\frac{1 - 2^{-4/3}}{1 - 2^{-2}} = \\frac{1.5}{0.75} (1 - 2^{-4/3}) = 2(1 - 2^{-4/3}) $$\nThe point estimate $\\hat{\\delta}$ is:\n$$ \\hat{\\delta} = \\ln(\\text{GMR}_{C_{\\max}}) = \\ln(2(1 - 2^{-4/3})) \\approx 0.187556 $$\nThe BE limits are:\n$\\theta_L = \\ln(0.8) \\approx -0.223144$\n$\\theta_U = \\ln(1.25) \\approx +0.223144$\nThe within-subject variance $\\sigma_W^2$ is:\n$$ \\sigma_W^2 = \\ln(1 + \\text{CV}^2) = \\ln(1 + 0.25^2) = \\ln(1.0625) \\approx 0.060623 $$\n\nThe distance from the point estimate to the BE limits are:\n$\\hat{\\delta} - \\theta_L \\approx 0.187556 - (-0.223144) = 0.410700$\n$\\theta_U - \\hat{\\delta} \\approx 0.223144 - 0.187556 = 0.035588$\nSince $\\theta_U - \\hat{\\delta}$ is smaller, the upper bound condition is more restrictive and will determine the sample size.\n$$ \\hat{\\delta} + z_{0.95} \\sqrt{\\frac{2 \\sigma_W^2}{N}} < \\theta_U $$\n$$ N > \\frac{z_{0.95}^2 (2 \\sigma_W^2)}{(\\theta_U - \\hat{\\delta})^2} $$\nSubstituting the values:\n$$ N > \\frac{(1.64485)^2 \\cdot (2 \\cdot \\ln(1.0625))}{(\\ln(1.25) - \\ln(2(1-2^{-4/3})))^2} $$\n$$ N > \\frac{2.70554 \\cdot (2 \\cdot 0.060623)}{(0.223144 - 0.187556)^2} $$\n$$ N > \\frac{2.70554 \\cdot 0.121246}{(0.035588)^2} $$\n$$ N > \\frac{0.32799}{0.0012665} \\approx 259.006 $$\nThe number of subjects $N$ must be an integer greater than $259.006$. The smallest such integer is $260$. For a standard two-sequence crossover design, the total number of subjects should be an even number to allow for balanced assignment to the two sequences (TR and RT). Since $260$ is an even number, it is a valid and practical minimum sample size.",
            "answer": "$$\\boxed{260}$$"
        }
    ]
}